Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Bibliographic Details
Main Authors: Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, Cohen, Ezra EW
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/
id pubmed-4289298
recordtype oai_dc
spelling pubmed-42892982015-01-11 Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial Burtness, Barbara Bourhis, Jean P Vermorken, Jan B Harrington, Kevin J Cohen, Ezra EW Study Protocol BioMed Central 2014-11-29 /pmc/articles/PMC4289298/ /pubmed/25432788 http://dx.doi.org/10.1186/1745-6215-15-469 Text en © Burtness et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Burtness, Barbara
Bourhis, Jean P
Vermorken, Jan B
Harrington, Kevin J
Cohen, Ezra EW
spellingShingle Burtness, Barbara
Bourhis, Jean P
Vermorken, Jan B
Harrington, Kevin J
Cohen, Ezra EW
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
author_facet Burtness, Barbara
Bourhis, Jean P
Vermorken, Jan B
Harrington, Kevin J
Cohen, Ezra EW
author_sort Burtness, Barbara
title Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
title_short Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
title_full Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
title_fullStr Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
title_full_unstemmed Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
title_sort afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase iii study (lux-head & neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
description
publisher BioMed Central
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/
_version_ 1613175045240127488

Similar Items